Adagio, flush with cash, launches large study of next-gen COVID-19 antibody

The privately held biotech believes its drug might treat or prevent infections from existing variants and future coronavirus strains, which could make it a threat to marketed therapies from Regeneron and Eli Lilly.

Show CommentsClose Comments

Leave a comment

%d bloggers like this: